SARS-CoV-2 IgG & IgM German Quick Test (not available for US-citizens)

!Now Available! - Results at the same business day (once the specimen arrives)

Qualitative detection of IgG and IgM antibodies against SARS-CoV-2

From human serum in the laboratory with laboratory validation of the results

Medical report is provided as an official document

Developed at the German Leibniz Institute

ArminLabs will gladly ship blood-collection testkits to you

If you're interested in receiving our special blood-collection testkits, please write us an Email to corona@arminlabs.com or give us a call.
Patients or therapists from the UK can contact info@aonm.org.


NEW Symptom-Checklist for COVID-19 available - DOWNLOAD THE CHECKLIST

The COVID-19 Symptomchecklist is a supportive tool in the clinical diagnosis of the practitioner/therapist.
It does not replace a detailed clinical diagnosis.

The German Quicktest offers these advantages:

• Accurate with high sensitivity and high specificity
• Can be performed using serum (internally validated)
• Tests for IgM and IgG antibodies
• Test can complement the direct detection of the pathogen (PCR)
• Validation via PCR has already been performed by the German test producer
• The test is CE certified, IVD registered and validated

The German IgM/IgG-Antibody-Quicktest can complement the direct detection of the pathogen (PCR)

Purposes that antibody testing can serve

In order to:

  1. Make a differential diagnosis to distinguish the infection from other acute pulmonary infections such as influenza
  2. Provide diagnostic assistance in the case of fresh infections
  3. Document current or past infection ~ 2 - 3 weeks after the onset of symptoms
  4. Track immune reactions in patients with a confirmed infection
  5. Possibly document potential immunity if a patient only has positive IgG antibodies

Serology can also be used to collect epidemiological data, which is especially important in the case of this largely unexplored new infection:

• Median seroconversion is 13 days after the onset of symptoms – half of the patients have no detectable antibodies within the first 12 days
• The seroconversion rate is almost 100% 20 days after the onset of symptoms